UCB is a global biopharma focused on severe diseases in two therapeutic areas: central nervous system and immunology operations.
The company is listed on the Euronext Brussels Stock Exchange and has its headquarters in Brussels, Belgium. It employs more than 8,500 people in more than 40 countries.
Financial Data
-
31st Dec 20 Source: CRO
- €0.1 million turnover
-
€0.3 million
profit - 0 employees
-
31st Dec 19 Source: CRO
- €1.1 million turnover
-
-€0.6 million
profit - 0 employees
- 12 more years available »
Ranking
By Turnover
(€0.1 million)- 960th in Top Companies
- 94th in Health
- 80th in Pharma
By Employees
(0)- 1026th in Top Companies
- 93rd in Health
- 78th in Pharma
-
- 0
- €0.1 million
Employees
- Claire Brading Country Manager
Latest News
- May 21 Consumer giant Procter & Gamble sells last Irish manufacturing plant
- May 21 Nama clashes with Fingal council over lands with space for up to 7,000 new homes
- May 20 Attempt by investors to appoint inspector to firm ‘without precedent’, court hears
- May 20 Amarenco and SSE among groups to win green Eirgrid contracts
- May 20 Cerberus collected €113m last year from Irish loans it bought after the 2008 crash